PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Randox Laboratories Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Randox Introduces New Liquid Ready-to-Use Fructosamine Reagent - The new liquid ready-to-use fructosamine assay from Randox is now available. The new formulation makes the assay easier to use requiring no offline preparation; based on an enzymatic method it also offers superior performance in terms of specificity
Randox Introduces New Liquid Ready-to-Use Fructosamine Reagent

 

NewswireToday - /newswire/ - Crumlin, Antrim, United Kingdom, 2011/09/26 - The new liquid ready-to-use fructosamine assay from Randox is now available. The new formulation makes the assay easier to use requiring no offline preparation; based on an enzymatic method it also offers superior performance in terms of specificity.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Fructosamine is a much earlier indicator of diabetic control compared to HbA1c providing useful information on an individuals average blood glucose levels over the preceding 14-21 days. In light of this, the American Diabetes Association (ADA) recognises fructosamine as a useful tool in monitoring diabetes control especially in situations where HbA1C cannot be reliably measured.

Due to its shorter time span, fructosamine is often measured to evaluate the effectiveness of medication changes after as little as two weeks. It is also routinely tested alongside glucose when monitoring insulin requirements during gestational diabetes. The needs of expectant mothers change frequently during pregnancy making fructosamine an ideal marker of glycaemic control.

The more commonly used HbA1c test is based on the presence of normal haemoglobin making it unsuitable in cases where the patient has a condition affecting the red blood cells e.g. haemolytic anaemia, sickle cell anaemia and thalasaemia. In such situations fructosamine is used as an alternative to tightly monitor glucose control.

The Randox fructosamine assay is based on an enzymatic method and therefore doesn’t suffer from non-specific interferences like conventional NBT based methods. All reagents are liquid ready-to-use for increased efficiency and productivity. Once opened they are stable onboard the analyser for 28 days at +10oC minimising the possibility of reagent waste.

The assay is highly precise with CVs less than 3.5% and offers a wide measuring range of 8.12 - 2065 µmol/l.

The Randox assay is fully automated and suitable for use on a wide range of clinical chemistry analysers with applications available on request for the most popular instruments. A dedicated reagent pack is also available for the Randox RX series of chemistry analysers. Two kit sizes are available one providing approximately 380 tests per kit and another providing up to 500 tests per kit. It is important to note that these numbers will vary according to the instrument used.

Randox can provide the complete package including calibrators and controls. Our dedicated fructosamine calibrator and controls are available in 3 x 1ml pack sizes with a working stability of 28 days at 2-8oC. Fructosamine is also available as a pilot scheme in our RIQAS (Randox International Quality Assessment Scheme) general chemistry programme.

In addition to fructosamine we can also provide high quality reagents for use in the diagnosis of diabetes and the monitoring of complications associated with diabetes. Available assays include Glucose, HbA1c, Cystatin C, D-3 Hydroxybutyrate, NEFA, B-2 Microglobulin, Creatinine and Total Protein.

About Randox

Headquartered in the United Kingdom, Randox Laboratories Ltd (randox.com) is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical chemistry, cardiology, forensic toxicology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. Our goal is to ‘revolutionise healthcare through continuously improving diagnostic solutions.’ We continue to achieve this year after year due to our commitment and significant re-investment in Research and Development. Our innovative approach to diagnostics allows us to develop revolutionary products, specifically designed to provide more efficient, higher quality and reliable results, ensuring patients receive the right diagnosis at the right time.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Randox Laboratories Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Randox Introduces New Liquid Ready-to-Use Fructosamine Reagent

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Charlotte Jess - Randox.com 
+44(0)28 4245 7832 marketing[.]randox.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Randox Laboratories Ltd securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Randox Laboratories Ltd / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Inferior Vena Cava Filters Market to Register a Strong Growth by 2025 Notes Persistence Market Research
Plasma Component Separator Market Set to Surge Significantly During 2017-2025 Says PMR
Persistence Market Research Releases Fertility Enhancing Treatment Market Snapshot by 2017-2025
Disposable Diabetes Devices Market Expected to Generate Huge Profits by 2025 Finds Reports Persistence Market Research
Cardiac Biomarkers Market Expected to Generate Huge Profits by 2017-2025 Reports PMR
Stone Management System Market Foreseen to Grow Exponentially Over 2017-2025 Finds PMR
Global Hemoglobinopathy Market Worth US$ 788M by 2024 According to Persistence Market Research
Dentsu Announces its Corporate Venture Capital Fund Dentsu Ventures Investment in Grail
Xenex Receives Top Honors from Frost & Sullivan for LightStrike™ - the Only Pulsed Xenon UV Disinfection System in the Healthcare Market
Partners HealthCare and GE Healthcare Launch 10-year Collaboration to Integrate Artificial Intelligence into Every Aspect of the Patient Journey
US Acute Care Solutions Celebrates 2-Year Anniversary
GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with Coronary CT Angiography
Telehealth Vendors Expand mHealth Portfolio to Conquer New Growth Opportunities Finds Frost & Sullivan
GE Healthcare Acquires Asymptote for Complete, Digitally-enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular
ANVISA Approval for EMCM Facilitates the Progress of Leader Biomedical Operations in Brazil

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit RightITnow Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)